Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
about
Function, regulation and pathological roles of the Gab/DOS docking proteinsImatinib for treating newly diagnosed chronic myeloid leukemia patientsImatinib for treating patients with chronic myelogeneous leukemiaThe proximal signaling network of the BCR-ABL1 oncogene shows a modular organizationCharting the molecular network of the drug target Bcr-AblCockayne syndrome protein B interacts with and is phosphorylated by c-Abl tyrosine kinaseFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaRegulation of myeloid leukaemia by the cell-fate determinant MusashiUbp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signalingRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedCould Vitamin D Analogues Be Used to Target Leukemia Stem Cells?Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsNuclear export of proteins and drug resistance in cancerMicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia CellsStructural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiaTargeting the SH2-Kinase Interface in Bcr-Abl Inhibits LeukemogenesisDissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domainsPonatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE studyAffinity-based proteomics reveal cancer-specific networks coordinated by Hsp90The CD155/poliovirus receptor enhances the proliferation of ras-mutated cellsEffective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismCounting highly cited papers for university research assessment: conceptual and technical issuesAging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitorsRole of ABL family kinases in cancer: from leukaemia to solid tumoursChronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responsesAllosteric interactions between the myristate- and ATP-site of the Abl kinaseCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsBCR-ABL affects STAT5A and STAT5B differentiallyData Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line EncyclopediaNon-antioxidant properties of α-tocopherol reduce the anticancer activity of several protein kinase inhibitors in vitroNMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.Intramolecular dynamics within the N-Cap-SH3-SH2 regulatory unit of the c-Abl tyrosine kinase reveal targeting to the cellular membraneThe Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding.The c-Abl tyrosine kinase regulates actin remodeling at the immune synapseReal-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells.A site-specific, multiplexed kinase activity assay using stable-isotope dilution and high-resolution mass spectrometry.CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemiaRNA quantification using gold nanoprobes - application to cancer diagnostics
P2860
Q21245511-4AE7C2C4-08F5-4FBF-8E5D-B33DBA83A721Q24186877-F3D347DB-FA89-4DC5-9FE1-238F65487625Q24241730-BDDC7202-AD08-4C16-B381-BF65EED90866Q24294830-035D84D3-AB00-41F1-B1D5-96655415C8B7Q24317707-2DCD34C3-2D33-4026-9CAB-7EB39C25CF51Q24318851-024D2514-0B99-4F08-B277-1F89F62AD819Q24605527-A8A9AF24-AA1C-4696-9C9A-F132788FBE04Q24634359-F574E1E6-2072-44C9-B61A-8EEE6BD037C0Q24685070-E0CA17D0-A0FC-48A5-A8DE-C5E42C1D1EF1Q26738514-8BFD9671-4AF4-415B-B45C-AB85E9334D7AQ26747513-6EE25FFE-C17C-412C-880A-1994896015F4Q26828528-80173ABC-E154-41A5-81D0-EC8506F9712DQ26849792-C7949646-BDE5-44BB-9152-821A1480BF50Q27012444-640D3A22-7400-4D5F-AAFA-E6C23368C5DAQ27343176-22E414FF-B363-414A-8211-73CA8CF0DE61Q27640723-D074BA88-54A7-4772-BF3C-D50C55885A98Q27675049-3696F4FF-B321-4585-95A1-46A0A44685C2Q27679810-8A1E350C-B6AD-4491-B3A7-6BCA00513261Q27852657-40E36C02-0BCB-4483-9462-FFEBCEBCC2FBQ28249103-DCE97325-99F0-4733-9D11-D2233DFD18FAQ28250501-B1624F35-0AA7-4B95-B87B-55BAB8073B41Q28275023-A8C65420-734E-4861-9652-36AE55CB499BQ28320491-AFCB3B67-581B-4009-B0BC-794F175EF882Q28395194-5DD1DAEC-DC47-48B5-8513-CA21B0572157Q28396643-10BDDE16-B195-4B95-93A2-17D085B1E2A0Q28475717-1302209E-EFA0-43C7-8FFF-847EE64F8741Q28476718-F6277235-C871-4A9B-AC96-E2D9F5D69F54Q28484913-7FC95E2C-45D4-4B36-81C2-9BCC4A9FA9CFQ28538914-693DD024-146C-4F52-AC57-B347B0E0C2CFQ28546078-389FF142-49AE-4B83-BE46-E54EB063E888Q28730066-B29B6591-D1C5-4645-9AF4-692A0FFC25E7Q30009530-22EF320C-9027-4C01-AA28-76A15E7F2E40Q30009592-3CAEA537-313E-4A19-B09B-0774C931DEAAQ30158039-A16E2266-EFC3-426C-9387-69ACE8BB075DQ30482430-027B0145-61A8-4546-9959-4882BD456A14Q30512706-78D0ECE1-06BA-4E55-8025-68B964AE75C0Q30837349-B49B3BF2-5D16-4EDD-8C4D-BFD52F66F78AQ33476095-1C1E0E52-A327-4274-B8E8-1D0FC3581BFAQ33728096-059D82BD-CA27-445B-88C0-0B8F6DCEEB14Q33748792-2AEFF564-DBDF-4E12-AAF8-D9A353AEE162
P2860
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
@ast
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
@en
type
label
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
@ast
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
@en
prefLabel
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
@ast
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
@en
P356
P1476
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
@en
P2093
Ruibao Ren
P2888
P304
P356
10.1038/NRC1567
P407
P577
2005-03-01T00:00:00Z